<PAGE>





                                    FORM 10-Q


                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D. C. 20549



[x] Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange
Act of 1934 For the quarterly period ended JUNE 30, 1999 or


[ ] Transition report pursuant to section 13 or 15(d) of the Securities Exchange
Act of 1934 For the transition period from ______ to ______


                                     1-9731
                              (Commission file No.)

                      ARRHYTHMIA RESEARCH TECHNOLOGY, INC.
             (Exact name of registrant as specified in its charter)




               DELAWARE                                   72-0925679
   (State or other jurisdiction of          (I.R.S. employer identification no.)
   incorporation or organization)




  1101 South Capital of Texas Highway
        Building G - Suite 200
             Austin, Texas                                  78746
(Address of principal executive office)                  (Zip code)




                                 (512) 347-9640
              (Registrant's telephone number, including area code)


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes X No___.



As of June 30, 1999 there were 3,440,601 shares of common stock outstanding.



This report consists of 10 pages.





<PAGE>



                      ARRHYTHMIA RESEARCH TECHNOLOGY, INC.

                                               TABLE OF CONTENTS

                                                   FORM 10-Q

                                                 June 30, 1999

<TABLE>

<S>                                                                                                              <C>
PART I - FINANCIAL INFORMATION.......................................................................................3

    Item 1.  Financial Statements....................................................................................3
    CONSOLIDATED BALANCE SHEETS......................................................................................3
    CONSOLIDATED STATEMENTS OF OPERATIONS............................................................................4
    CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY.......................................................5
    CONSOLIDATED STATEMENTS OF CASH FLOWS............................................................................6
    SUPPLEMENTAL NOTES TO CONSOLIDATED FINANCIAL STATEMENTS..........................................................7
    Item 2.   Management's Discussion and Analysis of Financial Condition and Results of Operations..................7

PART II - OTHER INFORMATION.........................................................................................10

    Item 1.  Legal Proceedings - none...............................................................................10
    Item 2.  Changes in Securities - none...........................................................................10
    Item 3.  Defaults Upon Senior Securities - none.................................................................10
    Item 4.  Submission of Matters to a Vote of Security Holders - none.............................................10
    Item 5.  Other Information - none...............................................................................10
    Item 6.  Exhibits and Reports on Form 8-K - none................................................................10
    SIGNATURES......................................................................................................10

</TABLE>

                                       2

<PAGE>




              ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
                          CONSOLIDATED BALANCE SHEETS
                                   (Unaudited)
<TABLE>
<CAPTION>
                                                                                            June 30,         December 31,
ASSETS                                                                                       1999               1998
                                                                                       -------------     ---------------
<S>                                                                                     <C>                <C>
Current assets:
  Cash and cash equivalents ......................................................      $    603,819       $    557,533
  Trade and other accounts receivable, net of allowance for doubtful accounts
        of $73,811 and $72,192 ...................................................         1,970,991          1,307,668
  Inventories, net ...............................................................           962,977          1,472,726
  Income Tax Recoverable .........................................................           262,810            262,810
  Other current assets ...........................................................            53,750             70,105
                                                                                       -------------     ---------------
    Total current assets .........................................................         3,854,347          3,670,842

Property and equipment, net of accumulated depreciation of $3,348,213 & $3,005,634         4,010,034          3,988,766
Patent and software development costs, net of accumulated amortization of $478,727
       and $457,204 ..............................................................           147,067             97,998
Goodwill, net of accumulated amortization of $821,659 & $756,084 .................         1,651,667          1,717,242
Deferred income taxes, net .......................................................           374,923            374,923
Other assets .....................................................................            62,750            140,373
                                                                                       -------------     ---------------
    Total assets .................................................................      $ 10,100,787       $  9,990,144
                                                                                       -------------     ---------------
                                                                                       -------------     ---------------
LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:
  Revolving credit facilities ....................................................      $          0       $          0
  Current maturities of bonds payable and long-term debt .........................           102,058            356,751
  Current maturities of capital lease obligations ................................            13,029             28,220
  Accounts payable ...............................................................           673,228            681,276
  Accrued liabilities and Other Liabilities ......................................           519,635            322,798
                                                                                       -------------     ---------------
    Total current liabilities ....................................................         1,307,950          1,389,045

Bonds payable, and other long-term debt, net of current maturities ...............           628,796            565,810
Capital lease obligations, net of current portion ................................            49,341             49,341
Deferred revenue .................................................................            17,519             27,036
                                                                                       -------------     ---------------
    Total liabilities ............................................................         2,003,606          2,031,232
                                                                                       -------------     ---------------
Shareholders' equity:
  Preferred stock, $1 par value; 2,000,000 shares authorized, none issued ........              --                 --
  Common stock, $.01 par value; 10,000,000 shares authorized;
      3,679,216 issued ...........................................................            36,792             36,792
Additional paid-in-capital .......................................................         8,909,307          8,909,307
Common stock held in treasury, 219,715 and 144,515 shares at cost ................          (992,494)          (913,084)
Unearned ESOP compensation .......................................................           (17,848)           (39,277)
Retained earnings (accumulated deficit) ..........................................           161,425            (34,826)
                                                                                       -------------     ---------------
    Total shareholders' equity ...................................................         8,097,182          7,958,912
                                                                                       -------------     ---------------
    Total liabilities and shareholders' equity ...................................     $  10,100,788       $  9,990,144
                                                                                       -------------     ---------------
                                                                                       -------------     ---------------
</TABLE>

The accompanying notes are an integral part of the consolidated financial
statements.



                                       3
<PAGE>


                             ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
                                    CONSOLIDATED STATEMENTS OF OPERATIONS
                                               (Unaudited)

<TABLE>
<CAPTION>
                                                    Three Months Ended June 30,        Six Months Ended June 30,
                                                      1999              1998              1999            1998

<S>                                               <C>              <C>               <C>              <C>
Net sales ..................................      $ 2,922,771      $ 2,845,232       $ 5,364,454      $ 5,274,344
Cost of sales ..............................        1,812,395        1,727,489         3,541,489        3,163,721
                                                  -----------      -----------       -----------      ------------
Gross profit ...............................        1,110,376        1,117,743         1,822,965        2,110,623
                                                  -----------      -----------       -----------      ------------
Selling and marketing ......................           75,772           86,530           146,370          183,492
General and administrative .................          537,752          540,963         1,038,579        1,078,670
Research and development ...................           21,795          112,156            66,655          212,204
Amortization of goodwill ...................           32,473           23,782            65,575           56,627
                                                  -----------      -----------       -----------      ------------
Total expenses .............................          667,792          763,431         1,317,179        1,530,993
                                                  -----------      -----------       -----------      ------------
Income from operations .....................          442,584          354,312           505,786          579,630
Other income (expense):
  Interest expense .........................           32,262           36,376            42,239           67,589
  Other ....................................           71,784           30,519           107,657           53,145
                                                  -----------      -----------       -----------      ------------
Income before income taxes and other charges          338,538          287,417           355,890          458,896

Provision for Asset Impairment .............                0          453,529                 0          453,529
                                                  -----------      -----------       -----------      ------------
Income (loss) before income taxes ..........          338,538         (166,112)          355,890            5,367
Income taxes (credit) ......................          141,156          (56,046)          159,639           24,573
                                                  -----------      -----------       -----------      ------------
Net income .................................      $   197,382      $  (110,066)      $   196,251      $   (19,206)
                                                  -----------      -----------       -----------      ------------
                                                  -----------      -----------       -----------      ------------
Net income per share .......................      $      0.06      $     (0.03)      $      0.06      $     (0.01)
                                                  -----------      -----------       -----------      ------------
                                                  -----------      -----------       -----------      ------------
Weighted average number of common
  and dilutive common equivalent
  shares outstanding .......................        3,440,601        3,563,101         3,440,601        3,563,101
                                                  -----------      -----------       -----------      ------------
                                                  -----------      -----------       -----------      ------------
</TABLE>

The accompanying notes are an integral part of the consolidated financial
statements.


                                       4

<PAGE>



                            ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
                                   CONSOLIDATED STATEMENTS OF CASH FLOWS
                                                (Unaudited)
<TABLE>
<CAPTION>

                                                                                           Six Months Ended June 30,
                                                                                      --------------------------------
                                                                                             1999             1998
                                                                                      ---------------  ---------------
<S>                                                                                        <C>             <C>
Cash flows from operating activities:
  Net Income ........................................................................      $ 196,251       $ (19,206)
  Provision for Asset Impairment ....................................................              0         453,529
  Adjusted Net Income ...............................................................        196,251         434,323

  Adjustments to reconcile net income to net cash provided by operating
  activities:
    Depreciation ....................................................................        342,579         330,142
    Amortization ....................................................................         87,098          78,502
    Deferred Revenue ................................................................              0               0
                                                                                     ---------------  --------------
  Changes in assets and liabilities:
    (Increase) Decrease in Trade and other accounts receivable, net .................       (663,323)        (50,166)
    (Increase) Deposits, prepaid expenses and other current assets ..................         16,355        (113,284)
    (Increase) Decrease in Inventories ..............................................        509,749         209,401
    (Decrease) in Accounts payable, accrued liabilities and other current liabilities          3,541        (619,841)
    Increase in Income taxes payable ................................................         47,515          40,607
    (Increase) Decrease in other assets .............................................              0          (4,057)
                                                                                     ---------------  --------------
Net cash provided by operating activities ...........................................        539,766         305,627
                                                                                     ---------------  --------------
Cash flows from investing activities:
  Net capital expenditures and fixed asset decrease .................................       (283,847)       (161,566)
  Deposits on capital equipment, acquisitions and other .............................         (2,377)         15,862
  Patent and software development expenditures ......................................        (70,592)        (15,537)
                                                                                     ---------------  --------------

    Net cash used in investing activities ...........................................       (356,816)       (161,241)
                                                                                     ---------------  --------------
Cash flows from financing activities:
  Net repayments of revolving credit facilities .....................................              0            (430)
  Increase in bonds payable due to amortization .....................................         62,986          24,000
  Reduction of unearned ESOP compensation ...........................................         21,429          21,429
  Principal paid for on treasury stock ..............................................        (79,410)             (1)
  Principal proceeds on long term debt, net .........................................              0               0
  Principal payments on long-term debt, net .........................................       (141,669)       (131,716)
                                                                                     ---------------  --------------
    Net cash used in financing activities ...........................................       (136,664)        (86,718)
                                                                                     ---------------  --------------
Net increase (decrease) in cash and cash equivalents ................................         46,286          57,669
Cash and cash equivalents at beginning of period ....................................        557,533         214,938
                                                                                     ---------------  --------------
Cash and cash equivalents at end of period ..........................................      $ 603,819       $ 272,607
                                                                                     ---------------  --------------
                                                                                     ---------------  --------------
</TABLE>


The accompanying notes are an integral part of the consolidated financial
statements.


                                       5


<PAGE>


                           ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
                      CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY


<TABLE>
<CAPTION>
                                                                                                  Retained
                                 Common Shares           Additional                 Unearned      Earnings
                            ------------------------     Paid-in       Treasury       ESOP        (Accumulated
                              Number       Amount        Capital        Stock       Compensation  Deficit)       Total
                            -----------   ----------    -----------   -----------   ------------  ----------   -----------
<S>                          <C>        <C>           <C>           <C>           <C>           <C>          <C>
January 1, 1996............. 3,564,511  $    36,792   $  8,899,261  $   (868,740) $  (167,848)  $  (546,718) $  7,352,747
Exercise of options.........
Maturity and repurchases of
  redeemable common stock...                                10,046                                                 10,046
ESOP payments...............                                                           42,857                      42,857
Treasury stock purchase.....    (1,410)                                  (10,047)                                 (10,047)
Sale of securities..........                                                                                            0
Net income..................                                                                        616,578       616,578
                            -----------   ----------    -----------   -----------   ----------    ----------   -----------
December 31, 1996........... 3,563,101       36,792      8,909,307      (878,787)    (124,991)       69,860     8,012,181
Maturity and repurchases of
  redeemable common stock...
Treasury stock purchase.....
ESOP payments...............                                                           42,857                      42,857
Net income..................                                                                         31,752        31,752
                            -----------   ----------    -----------   -----------   ----------    ----------   -----------
December 31, 1997........... 3,563,101       36,792      8,909,307      (878,787)     (82,134)      101,612     8,086,790
Treasury stock purchase.....   (28,400)                                  (34,297)                                 (34,297)
ESOP payments...............                                                           42,857                      42,857
Net income..................                                                                       (136,438)     (136,438)
                            -----------   ----------    -----------   -----------   ----------    ----------   -----------
December 31, 1998........... 3,534,701       36,792      8,909,307      (913,084)     (39,277)      (34,826)    7,958,912
Treasury stock purchase.....   (72,200)                                  (79,410)                                 (79,410)
ESOP payments...............                                                           21,429                      21,429
Net income..................                                                                        196,251       196,251
                            -----------   ----------    -----------   -----------   ----------    ----------   -----------
June 30, 1999............... 3,462,501  $    36,792   $  8,909,307  $   (992,494) $   (17,848)  $   161,425  $  8,097,182
                            -----------   ----------    -----------   -----------   ----------    ----------   -----------
                            -----------   ----------    -----------   -----------   ----------    ----------   -----------
</TABLE>


The accompanying notes are an integral part of the consolidated financial
statements.


                                       6

<PAGE>



SUPPLEMENTAL NOTES TO FINANCIAL STATEMENTS

         The unaudited interim consolidated financial statements and related
notes have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission. Accordingly, certain information and footnote
disclosures normally included in financial statements prepared in accordance
with generally accepted accounting principles have been omitted pursuant to such
rules and regulations. The accompanying unaudited interim consolidated financial
statements and related notes should be read in conjunction with the consolidated
financial statements and notes thereto included in the Company's most recent
Form 10-K covering the year ended December 31, 1998.

         The information furnished reflects, in the opinion of the management of
Arrhythmia Research Technology, Inc. ("ART"), all adjustments necessary for a
fair presentation of the financial results for the interim period presented.

         Interim results are subject to year-end adjustments and audit by
independent certified public accountants.

Inventories:

         Inventories consist of the following as of:
<TABLE>
<CAPTION>
                                                                     June 30,       December 31,
                                                                       1999             1998
                                                                  ---------------  ---------------
<S>                                                              <C>              <C>
Raw materials................................................... $      239,941   $      303,689
Work-in-process...............................................          177,611          330,812
Finished goods..................................................     1,555,412        1,861,060
                                                                  ---------------  ---------------
     Total......................................................     1,972,964        2,495,561
Allowance for slow-moving inventories...........................    (1,006,987)      (1,022,835)
                                                                  ---------------  ---------------
     Total...................................................... $      965,977   $   1,472,726
                                                                  ---------------  ---------------
                                                                  ---------------  ---------------
</TABLE>



Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations

LIQUIDITY AND CAPITAL RESOURCES

         At June 30, 1999, the Company had working capital of approximately
$2,537,000. At December 31, 1998, the Company had working capital of
approximately $2,282,000. The Company has a $3,500,000 working capital line of
credit with a bank, collateralized by accounts receivable and inventory of ART
and Micron Products Inc., which bears interest at prime plus .75% (8.5% at June
30, 1999). The working capital line of credit matures December 15, 1999 and did
not have an outstanding balance at June 30, 1999. The Company's lines of credit
are its primary source of operating funds and liquidity.

         Capital expenditures during the first six months of 1999 were
approximately $284,000 compared to $162,000 in 1998. This increase can be
attributed to the purchase of Scovill attaching machines by Micron, as well as,
the purchase of equipment to assist the molding area efficiency. Capital
expenditures are expected to increase in the third and fourth quarter as Micron
anticipates needing to purchase a new extruder if sales in the polymer operation
continue to increase. Normal capital expenditures are funded from operating cash
flows.

RESULTS OF OPERATIONS

         REVENUES for the second quarter ended June 30, 1999 were $2,922,771
when compared to $2,845,232 for the second quarter of 1998. Revenues from sales
of electrocardiographic ("ECG") sensors increased 4% for the quarter ended June
30, 1999, as compared to the same period in 1998. The sales mix for the Company
continues with ECG sensors making up the greater portion of sales and the
related cost of sales. Until 1996, ART acted as the exclusive distributor of
electrophysiology ("EP") products under its contract with their manufacturer,
Prucka Engineering, Inc. During 1998, ART received a 4% commission on net sales
of EP systems and accessories sold anywhere in the world, up to a ceiling of
$10,000,000 in total annual net sales. From January 1, 1999 through December 31,
2002, ART will receive a commission of 3% of the net sales of CardioLab systems
sold anywhere in the world, up to a ceiling of $10,000,000 in total net sales.
For revenues attributable to Prucka products that exceed $10,000,000 in any
year, ART will be entitled to receive 25% of the commission rate in effect that
respective year.



                                       7
<PAGE>

         Domestic and foreign sales for the first quarter are as follows:
<TABLE>
<CAPTION>
                         SECOND QUARTER                               FIRST SIX MONTHS

                1999          %         1998         %          1999       %          1998        %
                ----         ---        ----        ---         ----      ---         ----       ---
<S>           <C>            <C>     <C>            <C>      <C>           <C>     <C>           <C>
Domestic..    $1,262,910     43      $1,446,816     51       $2,506,71     47      $2,804,291    53

Foreign...     1,659,861     57       1,398,416     49       2,858,741     53       2,470,053    47
              ----------    ---      ----------    ---      ----------    ---      ----------   ---
Total ....    $2,922,771    100      $2,845,232    100      $5,365,454    100      $5,274,344   100
              ----------    ---      ----------    ---      ----------    ---      ----------   ---
              ----------    ---      ----------    ---      ----------    ---      ----------   ---
</TABLE>


         COST OF SALES increased by 5% for the quarter ended June 30, 1999, as
compared to the same period in 1998, because of the decrease in inventory at
Micron, as sales were higher than anticipated. Overhead costs at Micron for the
second quarter ended June 30, 1999, decreased by 6% as compared to the same
period of the prior year due to reductions in repairs and maintenance, and in
utility expenses.

         SELLING AND MARKETING expenses decreased as a percent of sales during
the second quarter ended June 30, 1999 by 13.3% as compared to the same period
for 1998. The current level of marketing operations is expected to increase
during the second six months of the year.

         GENERAL AND ADMINISTRATIVE expenses remained almost constant for last
year's numbers. The primary components of general and administrative expenses
are salaries and related payroll taxes and benefits, environmental monitoring
expenses, professional fees, and insurance costs. These expenses are expected to
continue at this level for the last six months of the year.

         RESEARCH AND DEVELOPMENT expenses decreased significantly by $90,000
for the second quarter ended June 30, 1999, as compared to the same period in
1998. The decrease is due primarily to salaries, travel and rent as ART moved to
new accommodation in November 1998. In addition, there were development costs in
1998 associated with converting the SAECG software to Windows and converting the
Cath Lab software to a Windows NT platform.

YEAR 2000

         GENERAL - ART's Company-wide Year 2000 Project is proceeding on
  schedule. The general Year 2000 concern is that many computer systems and
  software products will experience problems handling dates beyond the year 1999
  because the systems are coded to accept only two-digit entries in the date
  code fields. Art's executive staff has directed a centrally coordinated Year
  2000 Project team, made up of representatives from each of the company's
  departments and divisions, to address this issue of computer programs and
  embedded computer chips being unable to distinguish between the year 1999 and
  the year 2000. In 1998, ART began testing efforts addressing its, products,
  services, infrastructure, and internal business support applications. A
  detailed plan has been created and is currently being implemented which will
  ensure that all ART's business process and systems have been assessed for Year
  2000 Readiness by July 1999.

         PROJECT - The ART Year 2000 Project has been addressed on two fronts.
  ART is a manufacturing and distributor of medical products. These efforts were
  divided into four major sections, Company Products, Infrastructure (Internal
  IT Systems), Internal Non-IT systems, and Supply-Chain. The general phases
  common to all these sections are: (1) inventorying Year 2000 items; (2)
  assigning priorities to identified items; (3) assessing the Year 2000
  Readiness of items determined to be material to the Company; (4) repairing or
  replacing material items that are determined not to be Year 2000 ready; (5)
  testing material items; and (6) designing and implementing contingency and
  business continuation plans for each division. The company has engaged the
  service of an Information Technology consulting firm, Micro Support Group,
  Inc., to assist in the project management and in the conversion and testing of
  certain application software code.


         PRODUCTS - The year in the date field of all ART's products is in two
    digits and is only used as a reference to show when a test was performed. It
    is not used in any analytical calculations, hence none of the company's
    software products will have operational failures, invalid or incorrect
    results as a consequence of the year 2000 date change. Micron does not
    manufacturer any date-related products.

                                       8
<PAGE>


         INTERNAL IT SYSTEMS - The Company has assessed its internal information
    technology, or IT, systems, including business information systems, systems
    utilizing in it manufacturing and service operations, and systems providing
    electronic interfaces between the Company and its customers, to determine
    whether the Company operations will be interrupted by 2000 issue. The
    actions on this section are on schedule. The testing phase involved the
    testing of the Novell Server and the Real World Financial applications
    within Micron. Both systems passed all Year 2000 Readiness tests. ART will
    be migrating to these Year 2000 Ready systems during the second quarter of
    1999. ART expects to have addressed all internal Year 2000 issues identified
    in this process by June 1999.


         NON-IT SYSTEMS - ART has assessed the impacts of Year 2000 on non-IT
    systems. Non-IT systems include, but are not limited to telecommunications
    systems (PBX), security systems, HVAC systems, elevators, and utilities
    (Water, Gas, Electric, etc). Assessment of these systems is ongoing and is
    expected to be completed by July 1999.


         SUPPLY-CHAIN - ART has been working closely with suppliers and other
    third parties upon which it is dependent, to determine the extent of their
    Year 2000 Readiness. All critical suppliers and business partners to the
    Company have been contacted and the assessment of their Year 2000 readiness
    is underway. The ART Division expects this phase of the project to be on
    going with the risk assessment and contingency planning phase completed by
    July 1999 while Micron has completed this portion of the project.

         COST - Based on its investigation to date, the Company does not expect
    the total cost of its Year 2000 Project to have a material effect on the
    Company's business or financial results. The estimated cost of the Year 2000
    Project is approximately $17,600 at maximum. This cost is estimated to be
    distributed equally between fiscal 1998 and 1999.

         RISK - The Year 2000 Project is expected to significantly reduce the
    Company's level of uncertainty about the Year 2000 problem and, in
    particular, about the Year 2000 readiness of its material external agents.
    ART believes that, with the testing of its Financial Business system and the
    completion of this project as scheduled, the possibility of significant
    interruption of normal operations should be minimized.

         The Company recognizes that failure to correct a material Year 2000
    problem could result in an interruption in, or failure of certain normal
    business activities or operations. Such failures could materially and
    adversely affect the company's results of operations and financial
    condition. Due to the general uncertainly inherent in the Year 2000 problem,
    resulting in part from the uncertainty of the Year 2000 readiness of
    third-party suppliers and customers, the company is unable to determine at
    this time whether the consequences of Year 2000 failures will have a
    material impact on the Company's results of operations.



SAFE HARBOR UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995.

  Forward looking statements made herein are based on current expectations of
the Company that involves a number of risks and uncertainties and should not be
considered as guarantees of future performance. These statements are made under
the Safe Harbor Provisions of the Private Securities Litigation Reform Act of
1995. The factors that could cause actual results to differ materially include:
interruptions or cancellation of existing contracts, impact of competitive
products and pricing, product demand and market acceptance risks, the presence
of competitors with greater financial resources than the Company, product
development and commercialization risks and an inability to arrange additional
debt or equity financing.


                                       9
<PAGE>



                                          PART II - OTHER INFORMATION


ITEM 1.  LEGAL PROCEEDINGS - NONE

ITEM 2.  CHANGES IN SECURITIES - NONE


ITEM 3.  DEFAULTS UPON SENIOR SECURITIES - NONE


ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS - NONE


ITEM 5.  OTHER INFORMATION - NONE


ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K - NONE




SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                Arrhythmia Research Technology, Inc.
                                ------------------------------------



                                /s/  Anthony A. Cetrone,
                                President, Micron Products Inc.
                                Chairman of the Board

May 11, 1999

                                       10